cyrilzakka/clinical-trials huggingface dataset:
Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visits in Adults With NF

This is a prospective study through the NF clinic at Massachusetts General Hospital that will examine the relationship between psychosocial factors, health literacy, and satisfaction with the medical visit in adults with NF1, NF2, and Schwannomatosis. A total of 89 participants will be enrolled in the study.


Eligibility Criteria:
Inclusion Criteria:

1. Age 18 or older
2. Can read and speak English at or above the 6th grade level
3. Diagnosis of neurofibromatosis type 1, neurofibromatosis type 2, or schwannomatosis

Exclusion Criteria:

1. Severe active or untreated major mental illness that would interfere with study participation, to be determined at the discretion of the study investigator (e.g. untreated psychosis or suicidality)
2. Unable or unwilling to participate
3. Unable or unwilling to complete psychological assessments online via the REDCap or Assessment Center systems.
Investigating the Efficacy and Safety of the Combination Treatment of Huaier Granule and Biliary Drainage for MOJ

This study is designed to evaluate the efficacy and safety of the combination treatment of Huaier granule and biliary drainage for malignant obstructive jaundice.

After sign the informed consent, the, eligible patients are those who have completed the examinations within 2 weeks after the biliary drainage will enter the study and visit the study sites at Weeks 12, 24, 36, and 48. The follow-up duration is up to 48 weeks or until the death of patient during the study. The patients will be allocated to two groups based on whether being exposed to Huaier granule or not.

Study data will be collected prospectively, including the patients' baseline characteristics, chemo-/radio-therapy history, previous Huaier granule treatment, laboratory tests, imaging examinations, and various clinical endpoints including liver function, quality of life, status of survival, and safety.

This is a non-interventional study in patient population in real world. Therefore, the patients' treatment regimen will not be interfered, i.e., the patients will independently decide whether to take Huaier granule or not based on the recommendation from the clinician after the drainage. The patients will be allocated into different groups completely according to their treatment at clinic in real world. During the study, only the study required data and endpoints will be collected.

Eligibility Criteria:
Inclusion Criteria:

1. Male or female, aged between 18\~75 years;
2. Naïve patients who were diagnosed as malignant obstructive jaundice that was caused by carcinoma of head of pancreas, cholangiocarcinoma, gallbladder carcinoma, or duodenal papilla carcinoma, or carcinoma metastasis in hilar lymph nodes based on clinical assessments and/or pathological examination;
3. Total bilirubin \>80 umol/L;
4. Patients who are not indicated for or refused to receive surgical resection;
5. ECOG score ≤2 or KPS score ≥60;
6. Expected survival time ≥12 weeks;
7. Has signed and dated the informed consent in volunteer and are willing to comply with the data collection procedures by Investigator.

Exclusion Criteria:

1. Female patients who are pregnant or breastfeeding;
2. Patients who are receiving concomitant intravenous chemotherapy;
3. Patients whose malignant obstructive jaundice was caused by liver cancer;
4. Patients who have severe coagulation disorders and massive ascites;
5. Patients with obstructive jaundice who have concomitant fever;
6. Patients who are not applicable for or not willing to receive biliary drainage;
7. Patients who are not appropriate to participate in the study at discretion of the Investigator.
Artificial Intelligence Supported Intraoral Scanning.

Digitization (automation) of production stages with Computer-Aided Design and Computer-Aided Manufacturing (CAD/CAM) technologies has led to a digital revolution in dentistry, as in many other fields of the industry. In current dentistry, the digitalization process can be defined as direct and indirect workflow. The clinical reliability and success of the indirect digital workflow made possible by these technologies have been proven by scientific studies. With the development of intraoral scanners (IOS), a virtual model is obtained by direct digitalization. This method eliminated the conventıonale impression and dental cast model steps required for indirect digitalization. Intraoral scanners are used as an alternative to convantıonal impressions in single and short edentulous cases. It has already been emphasized that direct digitalization is a reliable alternative to the conventional impression method, as the clinical applicability, accuracy, and precision of the manufactured restorations have been scientifically verified. Therefore, the clinical use of direct digitalization is increasing (exponentially) day by day, and new upgraded versions of software, along with various modifications for the hardware equipment, are being developed. Integrating artificial intelligence (AI) supported software into the intraoral scanning process can be seen as the beginning of a new era for direct digitalization. Therefore the aim of this study is to evaluate the effect of artificial intelligence on the scanning time, the amount of data collected, and the image accuracy obtained.

It was planned intraoral scanning (3Shape TRIOS A/S, Copenhagen, Denmark) of the participants' mandible (n=21) with artificial intelligence (AI on) and without artificial intelligence (AI off). Reference equilateral triangles for scanning were digitally designed and produced with a 3D printer. Then these triangles bonded to the buccal surfaces of #34, #44, and the lingual surfaces of #36#46 teeth. The lower jaw of each participant was scanned by the same operator, in line with the recommended scanning protocol. Furthermore, scanning was performed randomly, with AI on and off.

The IOS software automatically recorded the data required for quantitative comparing the scanning time and the obtained images (TRIOS Scanning Version 1.18.310, 3Shape A/S). In order to compare the scanning effectiveness between the methods, the area data of the digital images of the triangular objects obtained during both scans were calculated in a computer environment with reverse engineering software (Geomagic design X version 2016.1.0, 3D Systems Inc. Rock Hill, SC).

Eligibility Criteria:
Inclusion Criteria:

* Completed growth and development
* Good oral hygiene habits and healthy periodontal status.
* Absence of missing teeth in mandibula (or no teeth loss in mandibular)
* Signing of the informed consent form
* No temporomandibular joint (TMJ) disorder

Exclusion Criteria:

* Volunteers who are not fulfilling the inclusion criteria
Ultrasound Guided TAP Block for Postoperative Analgesia After Abdominal Surgery.

Transversus abdominis plane (TAP) block is a novel type of peripheral nerve block that involves innervations of the anterolateral abdominal wall derived from T6-L1.It provides adequate post-operative pain relieve following the various abdominal surgeries. Theoretically, TAP block may replace the need for epidural analgesia after abdominal operations. The oblique subcostal approach of the TAP (OSTAP) block, which was de¬scribed by (Hebbard et al, 2010) , has been reported to provide analgesia to the entire anterior abdomen.

The transversus abdominis plane (TAP) technique, originally described by involves injection of local anaesthetic in the plane between the internal oblique and transversus abdominis muscle layers, with the aim of anaesthetising the intercostal nerves supplying the abdominal wall. Initially, the block used surface landmarks of the triangle of Petit (latissimus dorsi posteriorly, external oblique superiorly, iliac crest inferiorly) and a double fascial 'pop' (loss of resistance) to guide placement of the local anaesthetic. More recently, ultrasonography has been used to guide the delivery of the injectate into the appropriate plane, thereby increasing the accuracy of the Technique.

The duration of the TAB is limited to effect of administered local anesthetics. To prolong the block's duration, adjuvant medications were added to LA to magnify the effect of TAP block . Opiates such as morphine and tramadol have peripheral and central analgesic effects. Opiate receptors are present at the terminals of afferent peripheral nerves; therefore, administration of opiates peripherally might provide a significant analgesic effect.

Eligibility Criteria:
Inclusion Criteria:

BMI\< 30kg/m2.

* Age: 18-60 years.
* Sex: both males and females.
* ASA physical status: 1-II.
* Operation: Abdominal laparotomy.

Exclusion Criteria:

* Patient refusal.
* History of cardiac disease, psychological disorders, respiratory diseases including asthma, renal or hepatic failure.
* Coagulation disorders.
* Allergy to study medications.
* Chronic use of pain medications.
* Pregnancy.
* Respiratory tract in-fection within the last 2 weeks.
* Heavy smoker.
* Histo-ry of abdominal surgery or trauma.
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

The purpose of this study is to evaluate the Canadian Real Life Evaluation of the Effectiveness of Lupron in the Management of Prostate Cancer.

This is a Canadian Post Marketing Observational Study utilizing a prospective cohort design. Patients with Prostate Cancer who are prescribed Lupron will be entered into the study cohort and will be followed for a maximum of 36 months with recommended assessments at 3, 6, 12, 18, 24, 30 and 36 months after baseline. Treatment of the patients and follow up will be according to the physician's judgment, regional regulations and the product monograph.

Eligibility Criteria:
Inclusion Criteria:

* Has provided written informed consent allowing the use of their data for the study and providing permission for contact by the study personnel
* Diagnosed with Prostate Cancer
* Prescribed Lupron as part of his treatment by his treating physician

Exclusion Criteria:

* Currently participating in another prospective study including controlled clinical trials and observational studies.
* Patient cannot or will not sign informed consent
* Survival expectancy less than 2-3 years as per the treating physician's judgment
* Presence of other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of Prostate Cancer
* History of alcohol or drug abuse
* No longer than 6 months of therapy if currently on luteinizing hormone-releasing hormone (LHRH) treatment
Prospective Surveillance for Breast Cancer-Related Lymphedema

This randomized trial will test the effect of a prospective surveillance program for early detection and subclinical management of breast cancer-related lymphedema on the prevalence of chronic lymphedema.

Design and setting: This trial is a multi-center single-blind trial involving five hospitals in Denmark.

Procedure: All women booked for surgery for breast cancer at one of the study sites will be invited to participate. Women, who provide written informed consent, will have BIS measurements, and perform self-measurements of arm circumference. Further, participants will complete a sociodemographic questionnaire which will be used to ensure recruitment of a representable sample. This data will be collected at the hospital of surgery at pre-treatment. After surgery, women who had \>6 lymph nodes removed and have planned radiation therapy will be randomized 1:1 into intervention or control.

Eligibility Criteria:
Inclusion Criteria:

* female;
* ≥18 years;
* surgery for breast cancer (unilateral and bilateral) including ALDN with \>6 lymph nodes removed;
* can effectively communicate verbally in Danish;

Exclusion Criteria:

* surgery for breast cancer with SLNB or \< 6 nodes removed;
* pre-existing lymphedema (primary or secondary);
* previous treatment for breast cancer;
* pace maker;
* conditions known to cause swelling (pregnancy, congestive heart failure, chronic/acute renal disease, cor pulmonale, nephrotic syndrome, nephrosis, liver failure or cirrhosis, pulmonary edema, and thrombophlebitis or deep vein thrombosis in the arms).
Comparison of the 'CTR' Ratio With Standard Haemostasis Parameters in the Follow-up of Patients Undergoing Heparin Therapy

The Quantra(r) hemostasis analyzer (Stago) is a recent addition to the family of global hemostasis tests. It uses ultrasound-based technology to characterize the viscoelastic properties of a whole blood sample during coagulation. The Qplus(r) cartridge consists of independent channels, each containing different reagents that provide parallel measurements of 6 parameters.

This global test takes into account cellular elements such as platelets and red blood cells in clot formation, and also explores fibrinolysis. In addition, this test is of particular interest in delocalized biology, i.e. at the patient's bedside, and avoids the time-consuming laboratory centrifugation stage required for routine analyzers.

In practice, this test has been developed to monitor haemostasis in patients who may present with a range of coagulopathies of various etiologies, but also in the management of haemorrhagic patients, in order to adapt the administration of blood products in particular.

The Quantra (r) analyzer could therefore be of interest since it could be deployed in overseas operations to manage war casualties.

Recent studies (EACTAIC-ICCVA congress, October 2021) have shown that there is a good correlation between anti-Xa activity and the CTR (coagulation time ratio) parameter of the Quantra cartridge Qplus (TM), suggesting that this automated system could be used to manage anticoagulant therapy.


Eligibility Criteria:
Inclusion Criteria:

* Patients over 18 and affiliated to the french social security system
* Patients on curative heparin (low molecular weight heparin or non-fractionated heparin) for whom anti-Xa activity is prescribed or planned by the clinician
* Samples taken between working hours
* No opposition to study participation

Exclusion Criteria:

* Patients unable to consent
* Anti-Xa activity not prescribed
* Patients on another anticoagulant treatment or not anticoagulated about it
* Samples taken during non-working hours
* Pregnant or breast-feeding women
* Insufficient language level for understanding the information note
A Multicenter, Open Label Trial To Evaluate Pain Relief With Intravenous Followed By Oral Therapy With Parecoxib/Valdecoxib 40 Mg/Day For Treatment Of Post-Laparoscopic Surgery Pain

The objectives of this study were to assess the analgesic efficacy and safety of parecoxib/valdecoxib on post-laparoscopic surgery analgesia.

This study A3471107 was terminated on February 4th, 2005 due to enrollment difficulties, problems related to need for rescue medication, and perceptions about cardiovascular risk potentially associated with all NSAIDs.

Eligibility Criteria:
Inclusion Criteria:

* Patients who had undergone laparoscopic surgery
* Patients in need of post-surgical analgesia

Exclusion Criteria:

* Patients with an unexpected surgical complication which, in the Investigator's opinion, placed the patient at significantly higher risk for post-surgical complication(s), or for non-routine post-operative care requirements
* Patients who took any nonsteroidal anti-inflammatory drug or any analgesic within 48 hours prior to surgery
Global Sinus Surgery Registry

This study evaluates long-term safety and effectiveness of primary sinus surgery in a real-world population of adults with chronic rhinosinusitis (CRS) or recurrent acute rhinosinusitis (RARS). This post-market study will evaluate sinus surgery performed using commercially available sinus instrumentation (e.g. sinus balloon catheters, powered microdebriders, manual instruments).


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years or minimum adult age as required by local regulations
* The subject has a planned primary sinus surgery, which includes either traditional transnasal endoscopic sinus surgery (ESS), balloon sinus dilation (BSD) or a hybrid procedure
* Subjects diagnosed by ENT surgeon with chronic rhinosinusitis (CRS) or recurrent acute rhinosinusitis (RARS) per AAO-HNS or EPOS adult sinusitis clinical practice guidelines
* The subject has been informed of the nature of the registry and has consented to participate and authorized the collection and release of medical information by signing a consent form
* Subject is able to read and understand local language

Exclusion Criteria:

* Prior sinus surgery. Septoplasty, Nasal Polypectomy, Septorhinoplasty, Nasal Valve and Turbinate Reduction surgeries are not exclusions
* Planned surgery of any of the following : orbital decompression, skull base, neoplasm, lacrimal, UPPP, aesthetic surgery, Potts Puffy tumor, Draf III
* Planned external approaches (i.e. not trans-nasal)
* Planned off-label usage of balloon sinus dilation products.
* Balloon sinus dilation performed with a non-Acclarent balloon product
Telemental Health and Cognitive Processing Therapy for Rural Combat Veterans With Posttraumatic Stress Disorder

The immediate objective of this project was to evaluate the clinical effectiveness of a telemental health modality (video-teleconferencing) for providing an evidence-based group intervention (Cognitive Processing Therapy; CPT) to rural OIF/OEF Reservists, National Guardsmen, and veterans suffering with PTSD.

The project was a 5-year prospective randomized clinical trial which conducted a direct comparison of the VTC and in-person modalities using rigorous methodology and a sophisticated analysis of equivalency between clinical and process outcome domains. In addition, cost effectiveness of this modality will be addressed. Approximately 130 combat Reservists, National Guardsmen, or veterans were recruited from multiple clinical sites. Prospective participants received a comprehensive assessment at baseline to determine eligibility. The exclusion criteria selected are consistent with large PTSD randomized clinical trials as well as research using the CPT protocol with military populations with PTSD. The treatment was delivered twice a week over 6 weeks by a doctoral level psychologist. Quality control procedures were incorporated into the study's design to ensure integrity, fidelity and standard administration of the CPT intervention across both conditions. Participants received additional assessments at mid-treatment, immediately post-treatment, and at 3 and 6 months post-treatment. Outcome domains include: 1) clinical outcomes (symptom severity, social functioning); 2) process outcomes (perception of treatment, satisfaction, group therapy alliance, treatment compliance, and attrition and treatment credibility); and (3) cost-effectiveness outcomes.

Eligibility Criteria:
Inclusion Criteria:

* diagnosis of current combat related PTSD determined by the Clinician Administered PSTD Scale (CAPS-IV)
* participants taking psychoactive medications have to have a stable regimen for at least 45 days prior to study entry

Exclusion Criteria:

* active psychotic symptoms/disorder as determined by the SCID for DSM-IV
* active homicidal or suicidal ideation as determined by the structured clinical interview
* any significant cognitive impairment or history of Organic Mental Disorder as determined by the structured clinical interview
* active (current) substance dependence as determined by the SCID (lifetime substance dependence/abuse not excluded)
* unwillingness to refrain from substance abuse during treatment
* female veterans
Specific Effects of Escitalopram on Neuroendocrine Response

Citalopram, a selective serotonin reuptake inhibitor (SSRI), is used as a neuroendocrine probe in human subjects to assess serotonin (5-hydroxytryptamine; 5-HT) function as reflected in prolactin and plasma cortisol release. Citalopram is a racemic mixture of equal parts of the S(+) and R(-) enantiomers. The S(+) form ("escitalopram") has been identified as being the active isomer and inhibitor of serotonin reuptake and consequently antidepressant activity is associated almost exclusively with the S-enantiomer. Escitalopram has been shown to be approximately twice as potent as citalopram at the primary, high-affinity binding site on the human serotonin transporter. Interestingly, investigations have suggested an antagonistic interaction of the R- and S-enantiomer at an allosteric binding site on the serotonin transporter. This antagonism has been shown in animal studies where the addition of R-citalopram to escitalopram treatments significantly counteracts the antidepressant and anti-anxiolytic effects of escitalopram. From these clinical and experimental data, the researchers can anticipate that escitalopram would increase cortisol and prolactin in the neuroendocrine challenge paradigm more effectively than citalopram.

See above.

Eligibility Criteria:
Inclusion Criteria:

* The age range will be restricted to between 18 and 59 years of age.
* Subjects must be fit and have no history of significant illness.
* Subjects must have no risk factors for HIV or viral hepatitis.
* Subjects must be non-smokers, free of medication, and consume alcoholic and caffeinated beverages in moderation.
* Subjects must also be in good psychological health with no history of psychiatric illness.

Exclusion Criteria:

* Personal history of psychiatric illness, habitual smoking, illicit or prescription drug use, high intake of alcohol (\>10 drinks/week) or caffeine (\>500 mg caffeine/day), shift work, pregnancy, personal or familial history of seizures, significant medical illness or treatment in the last six months, significant physical or laboratory abnormalities, or current use of a weight loss diet.
* Women entering the study must be on a reliable form of birth control, i.e., tubal ligation, hysterectomy, oral contraceptives, abstinence, or vasectomy in partner.